GenoMed's Observation of Major Racial Difference in Prostate Cancer Confirmed - Medical News

Thursday 28 July 2005 - 12am PSTGenoMed Inc revealed today that it has actually received independent confirmation of an observation the Company orignally made in 2002 that acts in a different way in white and black males. In black males, angiotensin II advertises prostate cancer cells, and ACE preventions are protective. However in white males, angiotensin II safeguards against prostate cancer cells, and ACE preventions market prostate cancer cells.
In 2002, GenoMed published an unusual outcome: that task of angiotensin I-converting enzyme was positively linked with prostate cancer cells and PSA levels in African American males, However inversely linked with prostate cancer cells and PSA levels in Caucasians (Moskowitz DW. Is angiotensin I-converting enzyme a "master" illness genetics? Diabetic issues Technol Ther. 2002; 4(5):683 -711.

Table 9, p. 697; PDF file offered at: ). This was the first recommendation that ACE preventions, which block the manufacturing of angiotensin II, may shield black males against prostate cancer cells, However market prostate cancer cells in white males.
This observation was verified in a subsequent paper publishedsummer (Moskowitz DW, Johnson FE. The main duty of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Top Med Chem.


2004; 4(13):1433 -54), where ACE preventions were discovered to raise the chances of prostate cancer cells in a mostly white man proficient health center populationof 4.7 (Table 3). A "electrical wiring diagram" for prostate cancer cells in white males was proposed (Amount 12, p. 1446; PDF file offered at: ).
GenoMed's surprising outcome was confirmedPawlikowski and his group at the University of Lodz in Poland in work published in late 2004, which GenoMed just recently familiarized().
Said Dr. David Moskowitz, GenoMed's Chief Executive Officer and Principal Medical Policeman, "Dr. Pawlikowski's group used a prostate cancer cells cell line, DU-145, that was stemmed from a Caucasian man.

They discovered in vitro exactly what we discovered in vivo making use of genomic epidemiologic and pharmacoepidemiologic data in human person populaces: angiotensin II remarkably prevented the development of the Caucasian male's prostate cancer cells. The vital test will be to view if they note the other outcome with the CRL-2422 prostate cancer cells cell line, which is stemmed from an African American person. Our data anticipate that ACE preventions will slow the development of the CRL-2422 prostate cancer cells, and angiotensin II will market it, which is what angiotensin II does to most cancer cells lines."
Added Dr. Moskowitz, "Everyone health and wellness message is rather clear: every white male on an ACE prevention must be more closely checked for prostate cancer cells with a PSA level every 6-9 months. On the various other hand, every black male with prostate cancer cells must consider taking an ACE prevention to reduce development of the."
Concerning GenoMed
GenoMed, Inc. is a Following Generation DM(TM) Company whose mission is to improve person outcomesmolecular paths that trigger illness.

A St. Louis Company Diary post ( ) first reported that the Company used for patents based upon its finding that the ACE genetics is linked with many typical illness. The Company is currently marketing its protocols for avoiding kidney failing because of Diabetic issues and, and putting off the progression of. The Company is additionally conducting complimentary clinical trials for all cancers except prostate cancer cells in white males, and also all viral illness except infections. To enroll in GenoMed's complimentary clinical test for, simply click on the West Nile virus link at
Safe Harbor Statement
This press release consists of forward looking statements, including those statements referring to GenoMed, Inc.'s (the Company's) treatments. Words or expressions "should certainly,should,could," or similar expressions are planned to determine "positive statements" within the meaning of the Exclusive Stocks Litigation Reform Act of 1995.


Real results could differ materially from those predicted in the forward looking statements as an outcome of a number of risks and unpredictabilities. statements made herein are as of the day of this press release and must not be depended upon as of any kind of succeeding day. Unless otherwise requiredwe specifically disclaim any kind of obligation to update any kind of positive statements to mirror occurrences, advancements, unanticipated events or circumstances after the day of such Statement.
Get in touch with:
David Moskowitz MD FACP
GenoMed, Inc.
tel. 314-983-9933

Leave your comment